sarcopenie en obesitas loss of muscle mass due to elderly musclemassloss
Conditions
Interventions
-GHRH+ARG-test: Test contains GHRH: GHRH1-29
(GEREF, Serono, Italy) is
intravenous infused in an amount of 100µg/kg bodyweight after a 30 minute rest
period. Serum growth hormone concentrations were measured at 0, 15, 30, 60, 90
and 120 minut
Sponsors
Universiteit Maastricht, Human Biology
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: women, post-menopausal, age between 55-65, 8 visceral obese (BMI 27-33 and Waist/hip-ratio>0.85), 8 normal weight (BMI20-25, wasit/hip
Exclusion criteria
Exclusion criteria: Use of medication, instabel weight, disorders as cardiovascular diseases, diabetics, cancer, gelatin-allergic
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main endpoint of the study is the GH-concentration after ingestion of placebo and protein. This is determined by blood-sampling. | — |
Secondary
| Measure | Time frame |
|---|---|
| The second study endpoint is the insulin-concentration after ingestion of placebo and protein. This is determined by blood-sampling. Another endpoint is the correlation between the effect of standard clinical GHST and the protein-drink on GH-secretion. Correlation between the amount of visceral fat mass (estimated with DXA) and the GH concentrations after standard clinical GHST and protein-drink. | — |
Countries
Netherlands
Outcome results
None listed